RDB07831 - pGL3-AID R2 del.-02

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pGL3-AID R2 del.-02 (#RDB07831)

Reporter construct of mouse Aicda locus, position +384 to +1789.

Clone info.	Reporter construct of mouse Aicda locus with firefly luciferase. Cloned position, +384 to +1789.
Comment	Nat. Immunol. (2010) 2, 148-154, Fig. 2b.
Vector backbone	pGL3 (Plasmid)
Selectable markers	Amp^r
Gene/insert name	Mouse Aicda genomic DNA
Depositor\|Developer	Honjo, Tasuku \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] MTA, for use for for-profit purpose [Word] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 提供同意書 (MTA, 営利目的用)[Word] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

必要書類

提供依頼書

[依頼書の記入例

]
提供同意書 (MTA, 非営利学術目的用)[Word

] [MTAの記入例

]
提供同意書 (MTA, 営利目的用)[Word

]
手続きの概要は、「提供申込みについて[link]」をご覧ください。

MTAに書く使用条件

利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。
MTAに書く付加的使用条件：
本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07831	pGL3-AID R2 del.-02	DNA solution	JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pGL3-AID R2 del.-02 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07831).

Reference section:

Tran, T.H., Nakata, M., Suzuki, K., Begum, N.A., Shinkura, R., Fagarasan, S., Honjo, T., Nagaoka, H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB07831_A4Gi.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: ME-1290Rv Sequence file: RDB07831_A4Gia.seq
>07831_07831_A4Gi_ME_1290Rv_H11_23.ab1 1 AGGGCAATTC ATTTTATGTT TCAGGTTCAG GGGGAGGTGT GGGAGGTTTT TTAAAGCAAG 61 TAAAACCTCT ACAAATGTGG TAAAATCGAT AAGGATCCAA GAGGTCTAGC AACTCCTTAC 121 TAAAAACAGT AGTGGTTATT TTCACAATTA TTTGGCAAAT ATCCAACATC TTAAGACTCG 181 CATGGGGAGT CTTTACAGGA ATTATTTAGT TATAGCAAGA AGATTTGTAC TTCTCAAAAA 241 AAAAAAAAAA CTAAACATTT GAAATGAATT GCTTGCAACT CATTACAATG GTGTCTATTG 301 AAGGAAAGAA TTTCATTAAA ACAGGCAATT TAGTGTTATA GACTCAACTG TTAAACACTT 361 GGTGACATTT TTACTGTTTA ATTCATCTAT GCAGAGATTT CTTAGCTTCT TGAAAGCTTT 421 TATATGCAGC TCATGATGAG CCATTATCAG AAATTTCTCT CTTGATTTTT ACATTTATTG 481 CCAGTGTGTG AGTCACTATG CCTAAAGCCC ATACACTTGA GCTCACTTCC GTTTGGCTAT 541 GAGGTTTAGA ATATGGAGTT AATATAGCTA ATGGTAGCAG GGTGTTCTTC AAATTCCAGA 601 TTTTTCCTTT CTTGTCTTCC TTCTTTCTTT TTGTTACCCT TCTCCTACCC CCTCTTCTTC 661 TCCCCCTCCT CCTCTTCCTC CCTCCTCCCC ATCTCTTCCC CTCCTCTTCT CCCTCCTCCC 721 CCTCCTCTTC CCCTTCTCCA CTTCCCCCTC TTCCTCCTCT TCCTCCTCCT TCTCCTGCTC 781 CCCATCTCTT TCCCTCCTCT TCTCCCTCCT CCTCCTCTTT GGCCCCTTCT CTCTTCCCCC 841 CTCCTCCTCT CCCTTTTCCT TCTCCTCTTC TCTCCCTCTC TTCCCGTTTC TCCTCCAACT 901 CTCCTTCACC CTATCAGGGA CCACATTGAG ACTTCACACA TGCTAGACAA GTAATCTGGC 961 ACATAATTAC ATCCTGGAGT CTTGAAAGCA ACAGACTGAA CGACGACGAC GGCTGGACGA 1021 CAAACCAACA TGTTTCCAAG AGCAAGCACA CGCCTGAACT GCTTCGGTTT AATGGAATTG 1081 ACCACCTGAA TAATGTCTGA GGGAGTTCCA GAAAAGTCCT GACATGGCCA AG //
Primer: pGL3_RV4 Sequence file: RDB07831_A4Gib.seq
>07831_07831_A4Gi_Rv4_A12_03.ab1 1 GCAGGACTGA TGGGTTGAGG CTCTCAAGGG CATCGGTCGA CGGATCCCCC CTCAACTCTA 61 GCTAGGAGCC TATTTCCAGC TCCCTCTCCT CGGGATGTCC CTCCCGGTAA GGAGGACTTT 121 GCTAGGTGGT GTCCCAAACC TGTAGATCGC CAGCTGCTGA GACAGCTGTG CTCCTTGAGG 181 CAGAACCTTA GCTGCTTCCC CAGCAATGCA AACCAGACTC AAGGGGTTAA AAATAATCCC 241 AGCCTAGTAG CAGGGCTGCC TTGAGTTACT CGCTGCCCTT GCTCCAGTCC GTGCCGTGCC 301 ATCCTGTGTC TCTCCACTGT CTTGTTTGCT TCTCCCTGAA TCTCAGCCTC GTCTTTGCTT 361 TGCATTTTGC CATGCTCATG CATTTCTCTC GGACCCTTCT CCATCAGGAC ATAGATCTCA 421 GATTTGGTTT CAAAATTCAC TATAAACCCA GAAGCAGCTC AGGCTGTCTG CCTGCCTCCT 481 GTGAACATTT GTTTGTTTGT CTGTCTGTCT GTCTGTCTGT CTGTCTGTCT GTTTGCTTTT 541 TGAGGGCTCA GGATGTAATT AAGTGGCAGA TTACTTGTCT AGCATGTGTG AGGTCTTCAA 601 TGTGGTCCCT GATAGGGGTG AGGGAGAGTG GGAGGAGGAA AGGGGGAGGA GAGGGGGGGG 661 ATGGAGTCGG ACGATGAGGA TGAGGGCCAT GAAGAGGGTC AGCTCCATCC GGTGCAAGAG 721 GAGGATGAGG AGGGAGAAGA GGAGGGAAAG AGATGGGGAG CAGGAGAAGG AGGAGGAAGA 781 GGAGGAAGAG GGGGAAGAGG AGAAGGGGAA GAGGAGGGGG AGGAGGGAGA AAGAGGAGGG 841 GAAGAGATGG GGAGGAGGGA GGAAGAGGAG GAGGGGGAGA AGAAGAGGGG GTAGGAGAAG 901 GGTACAAAAA AGA //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original	Tran, T.H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Resource search

Link

Other resources in our bank

mouse Aicda

External Database
Mouse Aicda

Reference sequence